<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100123</url>
  </required_header>
  <id_info>
    <org_study_id>CTO 0807</org_study_id>
    <nct_id>NCT03100123</nct_id>
  </id_info>
  <brief_title>AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study</brief_title>
  <acronym>APPLE</acronym>
  <official_title>A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Evaluating Aspirin Versus Low-molecular-weight Heparin (LMWH) and Aspirin in Women With Antiphospholipid Syndrome and Pregnancy Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The APPLE pilot trial is a feasibility study that is a multicentre, open-label, randomized
      controlled trial. Pregnant women with antiphospholipid syndrome (APS) and a history of late
      (â‰¥10 weeks gestation) or recurrent early (2 &lt;10 weeks) pregnancy loss will be recruited.

      Eligible and consenting subjects will be assigned to one of two study arms: open-label
      low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin
      (ASA) daily until delivery, or open-label low-dose aspirin daily from randomization until
      delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this pilot trial is to determine the feasibility of conducting a multicenter
      randomized full trial evaluating antepartum prophylaxis with ASA versus LMWH/ASA in women
      with confirmed APS and a history of late or recurrent early pregnancy loss.

      Given the large sample size needed to adequately power a large multicenter trial that
      assesses the efficacy of ASA alone versus LMWH/ASA, the investigators first need to determine
      if it is possible to meet minimum recruitment rates needed for a full multicenter trial. If
      the pilot feasibility trial is successful, then the secondary outcomes collected will be used
      in the analysis of the full multicenter trial.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Pilot deemed not feasible by Steering Committee due to recruitment rate.
  </why_stopped>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Actual">October 7, 2019</completion_date>
  <primary_completion_date type="Actual">October 7, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible and consenting subjects will be assigned to one of two study arms. Randomization is stratified by 'high-risk' or 'non-high risk' laboratory criteria and the timing of pregnancy loss (late loss or no late loss).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study Feasibility: Mean Recruitment Rate Per Center Per Month</measure>
    <time_frame>24 months</time_frame>
    <description>The primary feasibility outcome of the pilot trial is the mean recruitment rate per center per month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Essential Documents</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of sites requiring &gt;18 months to obtain all required approvals/contracts from time of delivery of all study documents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eligibility</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of screened patients who meet eligibility criteria (i.e. patients who meet inclusion criteria and are also eligible based on exclusion criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consent</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of eligible subjects who provide consent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawals/Loss to Follow-up</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of withdrawals/loss to follow-up among randomized patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crossover Rate</measure>
    <time_frame>52 weeks</time_frame>
    <description>Crossover rate between standard of care and experimental study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Drug Compliance</measure>
    <time_frame>52 weeks</time_frame>
    <description>Level of compliance with study drug through patient recall and patient medication diary.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Antiphospholipid Syndrome in Pregnancy</condition>
  <condition>Pregnancy Loss</condition>
  <arm_group>
    <arm_group_label>Standard of Care Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label low-dose Aspirin 81 mg daily from randomization until delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81 mg</intervention_name>
    <description>Aspirin 81 mg po daily in tablet form.</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>Acetylsalicylic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-molecular-weight heparin</intervention_name>
    <description>The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.</description>
    <arm_group_label>Standard of Care Arm</arm_group_label>
    <other_name>Tinzaparin</other_name>
    <other_name>Dalteparin</other_name>
    <other_name>Enoxaparin</other_name>
    <other_name>LMWH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed pregnancy;

          -  18 years or older;

          -  Two or more unexplained pregnancy loss before the 10th week of gestation, AND/OR one
             or more unexplained pregnancy loss at or beyond the 10th week of gestation;

          -  One or more APS laboratory criteria present, according to the revised Sapporo
             criteria;

        Exclusion Criteria:

          -  Greater than 11 weeks +6 days gestational age at time of randomization;

          -  Indication(s) for prophylactic or therapeutic-dose anticoagulation;

          -  Contraindication to heparin or aspirin;

          -  Received 7 or more doses of LMWH;

          -  Previous participation in the trial;

          -  Geographic inaccessibility;

          -  Refused consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Rodger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leslie Skeith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <results_first_submitted>March 25, 2020</results_first_submitted>
  <results_first_submitted_qc>March 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2020</results_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03100123/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care Arm</title>
          <description>Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
Low-molecular-weight heparin: The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.</description>
        </group>
        <group group_id="P2">
          <title>Experimental Arm</title>
          <description>Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
Aspirin 81 mg: Aspirin 81 mg po daily in tablet form.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>0 participants were enrolled in the standard of care arm.</population>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care Arm</title>
          <description>Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
Low-molecular-weight heparin: The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.</description>
        </group>
        <group group_id="B2">
          <title>Experimental Arm</title>
          <description>Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
Aspirin 81 mg: Aspirin 81 mg po daily in tablet form.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Study Feasibility: Mean Recruitment Rate Per Center Per Month</title>
        <description>The primary feasibility outcome of the pilot trial is the mean recruitment rate per center per month.</description>
        <time_frame>24 months</time_frame>
        <population>1 participant was recruited (ASA alone arm) and the pilot trial was stopped early due to feasibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Arm</title>
            <description>Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
Low-molecular-weight heparin: The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Experimental Arm</title>
            <description>Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
Aspirin 81 mg: Aspirin 81 mg po daily in tablet form.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Feasibility: Mean Recruitment Rate Per Center Per Month</title>
          <description>The primary feasibility outcome of the pilot trial is the mean recruitment rate per center per month.</description>
          <population>1 participant was recruited (ASA alone arm) and the pilot trial was stopped early due to feasibility.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Essential Documents</title>
        <description>Proportion of sites requiring &gt;18 months to obtain all required approvals/contracts from time of delivery of all study documents.</description>
        <time_frame>18 months</time_frame>
        <population>Site #1 was able to obtain all applicable approvals and begin recruitment in 12 months. Not applicable applicable for site #2 as study was closed early due to low recruitment.</population>
        <group_list>
          <group group_id="O1">
            <title>Approval Timeline</title>
            <description>Sites requiring &gt;18 months for all approvals</description>
          </group>
        </group_list>
        <measure>
          <title>Essential Documents</title>
          <description>Proportion of sites requiring &gt;18 months to obtain all required approvals/contracts from time of delivery of all study documents.</description>
          <population>Site #1 was able to obtain all applicable approvals and begin recruitment in 12 months. Not applicable applicable for site #2 as study was closed early due to low recruitment.</population>
          <units>Sites</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eligibility</title>
        <description>Proportion of screened patients who meet eligibility criteria (i.e. patients who meet inclusion criteria and are also eligible based on exclusion criteria).</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Screened Patients Who Met Eligibility Criteria</title>
            <description>Screened patients who meet eligibility criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Eligibility</title>
          <description>Proportion of screened patients who meet eligibility criteria (i.e. patients who meet inclusion criteria and are also eligible based on exclusion criteria).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consent</title>
        <description>Proportion of eligible subjects who provide consent.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Consented Eligible Patients</title>
            <description>Eligible patients who provided consent</description>
          </group>
        </group_list>
        <measure>
          <title>Consent</title>
          <description>Proportion of eligible subjects who provide consent.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Withdrawals/Loss to Follow-up</title>
        <description>Proportion of withdrawals/loss to follow-up among randomized patients.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Withdrawal/Lost to Follow-up</title>
            <description>Withdrawal/Lost to follow-up among randomized patients</description>
          </group>
        </group_list>
        <measure>
          <title>Withdrawals/Loss to Follow-up</title>
          <description>Proportion of withdrawals/loss to follow-up among randomized patients.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crossover Rate</title>
        <description>Crossover rate between standard of care and experimental study arms.</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crossover Rate</title>
            <description>Crossover rate between standard of care and experimental study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Crossover Rate</title>
          <description>Crossover rate between standard of care and experimental study arms.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Drug Compliance</title>
        <description>Level of compliance with study drug through patient recall and patient medication diary.</description>
        <time_frame>52 weeks</time_frame>
        <population>No participants in standard of care arm</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Arm</title>
            <description>Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
Low-molecular-weight heparin: The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.</description>
          </group>
          <group group_id="O2">
            <title>Experimental Arm</title>
            <description>Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
Aspirin 81 mg: Aspirin 81 mg po daily in tablet form.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Drug Compliance</title>
          <description>Level of compliance with study drug through patient recall and patient medication diary.</description>
          <population>No participants in standard of care arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The AE reporting period for this trial begun upon randomization, and ended 30 days after receiving the last dose of study drug.</time_frame>
      <desc>AEs were elicited, monitored and recorded throughout the study. For each participant, AEs were submitted to the trial office after each follow-up visit. The investigator is to report all directly observed AEs and all AEs spontaneously reported by the participant. In addition, each participant will be questioned about AEs at each clinic visit following initiation of treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care Arm</title>
          <description>Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
Low-molecular-weight heparin: The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.</description>
        </group>
        <group group_id="E2">
          <title>Experimental Arm</title>
          <description>Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
Aspirin 81 mg: Aspirin 81 mg po daily in tablet form.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Leslie Skeith</name_or_title>
      <organization>Ottawa Hospital Research Institute</organization>
      <phone>403-944-5246</phone>
      <email>laskeith@ucalgary.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

